Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

First, the bad news: It will be a longer wait before the first product with regenerative medicine advanced therapy (RMAT) designation gets approved, as the US Food and Drug Administration issued a complete response letter (CRL) to Enzyvant Sciences Ltd. for its congenital athymia candidate RVT-802.

The news comes just as the 21st Century Cures Act, which authorized the RMAT pathway, is about to hit its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers